Evaluating immune system markers in elderly patients
Evaluation of Monocyte Expression of HLA-DR (mHLA-DR) in the Multi-pathological Elderly Subject in Geriatric Service
This study looks at the immune system of elderly patients over 75 in the hospital to see how their multiple health issues affect their immune response.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 75 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | Eculizumab, chemotherapy, immunotherapy |
| Locations | 2 sites (Caluire-et-Cuire and 1 other locations) |
| Trial ID | NCT06513520 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the immune status of elderly patients over 75 years old who are hospitalized in geriatric units. It aims to explore the effects of multiple chronic pathologies on monocyte expression of HLA-DR, a marker of immune alteration, particularly in the context of immunosenescence. By analyzing blood samples from patients with both acute and stable conditions, the study seeks to provide insights that are currently lacking in existing research, which often excludes multi-pathological elderly patients. The findings could help tailor better healthcare strategies for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates are elderly patients aged over 75 who are hospitalized in geriatric units and have either acute or stable health conditions.
Not a fit: Patients under legal protection or those receiving exclusive comfort care will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of immune health in elderly patients with multiple chronic conditions.
How similar studies have performed: While studies have explored immune aging, this approach focusing on multi-pathological elderly patients is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For all patients: * Patients aged over 75 hospitalised in one of the geriatric units defined as the research sites; * Patient affiliated to a social security scheme; * Patients or relatives who have been informed and have no objections to the research. To be eligible in the acute situation sub-population: - Patients presenting with an acute episode on admission or following a stay in the research sites; The acute episode is defined, for example, by an infection, cardiac decompensation, a complicated fall, acute renal failure, any acute or decompensated cardiovascular pathology, any discovery of cancer that has not been stabilised. To be eligible in the stable situation sub-population: - A patient who has not had an acute episode for at least 7 days. Exclusion Criteria: For all patients: * Patients under legal protection: curatorship, guardianship, safeguard of justice ; * Patients under exclusive comfort care for whom it has been decided not to take a blood sample; * Patients undergoing long-term antibiotic treatment, i.e. with no defined stopping date; * An immunocompromised patient or a patient undergoing immunosuppressive treatment (for example: HIV infection, a patient awaiting solid organ transplantation, a patient undergoing haematopoietic stem cell transplantation, a patient undergoing chemotherapy for a solid tumour or haematological malignancy, a patient suffering from an auto-immune disease and being treated with immunotherapy and/or immunosuppressive therapy and/or biotherapy, an asplenic or hyposplenic patient, a patient undergoing experimental potentially immunosuppressive treatment, a patient undergoing Eculizumab treatment, a patient presenting a hereditary immune deficiency). For patients in an acute clinical situation: - Patient previously included in the same sub-population.
Where this trial is running
Caluire-et-Cuire and 1 other locations
- Dugoujon Hospital — Caluire-et-Cuire, France (Recruiting)
- Croix Rousse hospital — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Sylvain GAUJARD, MD
- Email: sylvain.gaujard@chu-lyon.fr
- Phone: +33 4 26 73 26 81
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.